Rosetta Genomics Ltd. (ROSG) announced Wednesday morning that Novitas informed the company that it plans to cover the company's miRview mets² assay for all Medicare beneficiaries. MiRview mets² accurately identifies the primary tumor of origin in primary and metastatic cancer.
Rosetta Genomics gapped up Wednesday and rose steadily throughout the first hour of trade. The stock finished up by 3.37 at $4.99 on the highest volume of the year and broke out to over a one-month high.
For comments and feedback: editorial@rttnews.com